Palo Alto, United States
DELFI Diagnostics, founded in 2019, is at the forefront of the convergence of AI and biotechnology, focusing on health care through early cancer detection. Their slogan, "Saving lives through early cancer detection," encapsulates their mission of leveraging artificial intelligence and whole genome sequencing to identify unique DNA fragmentation patterns in blood, a critical innovation in cancer diagnostics.
Headquartered in the United States, the company’s groundbreaking approach has attracted significant investment. In a recent Series B funding round on July 18, 2022, DELFI Diagnostics secured $225.00M from prominent investors, including OrbiMed, T. Rowe Price, and Brown Advisory, among others. This substantial financial backing from trusted names like Cowen Digital and Foresite Capital underscores confidence in their technology and positioning in the healthcare market.
The company's innovative use of AI positions it uniquely for future growth, potentially transforming the global cancer detection landscape.
